Clinical trials: Partial Response
Healthy
A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.
The study compares the plasma concentrations of PF-02413873 after administration of several doses as suspension and as tablets
- Trial name
- NCT00857571
- Testing
- 150 mg Suspension, 30 mg Suspension, 400 mg Suspension
- Where
- Singapore
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Study is a double-blind, randomized, placebo controlled, dose escalating study. The primary objective of this study is to evaluate the safety, tolerability and feasibility of a single intravenous infusion of allogeneic…
- Trial name
- NCT01851070
- Testing
- Allogeneic Mesenchymal Precursor Cells, Normal Saline
- Where
- 23 sites in United States, Australia
- Volunteers
- 48 people
- Sponsor
- Mesoblast, Ltd.
Rheumatoid Arthritis
A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis
The objective of this trial is to compare the efficacy of Certolizumab (CZP) (CDP870) in combination with Methotrexate (MTX) to MTX alone in the treatment of signs and symptoms in patients with active rheumatoid arthritis (RA)…
- Trial name
- NCT00993317
- Testing
- CDP870 200mg, Methotrexate
- Where
- 15 sites in South Korea
- Volunteers
- 127 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Sensitivity in Esophagus
Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)
The purpose of the study is to compare sensitivity of visceral pain in the esophagus using different pain stimuli.
- Trial name
- NCT01019928
- Testing
- AZD1386
- Where
- 2 sites in Denmark, Sweden
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Lung Cancer, Non Small Cell Lung Cancer
EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)
Primary trial objective in this single arm trial is to assess the safety and tolerability of Selectikine (EMD 521873) given in combination with and local tumor irradiation and to determine whether the maximum tolerated dose (MTD)…
- Trial name
- NCT00879866
- Testing
- EMD 521873
- Where
- 3 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Ovarian Cancer
Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
This is an open-label, single-arm, international, multicenter Multiple Patient Expanded Access Program (MPEAP). The program is designed to provide treatment access to olaparib tablets for patients with platinum-sensitive relapsed…
- Trial name
- NCT03079687
- Testing
- Olaparib tablets
- Where
- 13 sites in United States
- Sponsor
- AstraZeneca
Primary Biliary Cholangitis
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA).
- Trial name
- IDEAL (NCT06060665)
- Testing
- Seladelpar 10 mg
- Where
- 45 sites in United States, Canada
- Volunteers
- 96 people
- Sponsor
- Gilead Sciences
Focal Segmental Glomerulosclerosis
Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis
Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis
- Trial name
- AURONA™ (NCT03598036)
- Testing
- Voclosporin
- Where
- 23 sites in United States, Dominican Republic
- Volunteers
- 5 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Major Depressive Disorder
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
- Trial name
- NCT01234558
- Testing
- GLYX-13
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Leukaemia, Myelocytic, Acute
Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy
The purpose of this study is to evaluate the clinical activity and safety of a WT1 Antigen-Specific Cancer Immunotherapeutic (WT1 ASCI) as post-induction therapy in adult patients with WT1-positive AML presenting a suboptimal…
- Trial name
- NCT01051063
- Testing
- GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A
- Where
- 22 sites in United States, France and 1 more
- Volunteers
- 17 people
- Sponsor
- GlaxoSmithKline
Pain
Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.
Opioids are potent painkillers but come with serious adverse effects ranging from addiction to potentially lethal respiratory depression via activation of μ-opioid receptors (MOP) at specific sites in the central nervous system.
- Trial name
- NCT05491785
- Testing
- Cebranopadol 600 µg, Cebranopadol 800 µg, Cebranopadol 1000 µg
- Where
- 2 sites in Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
Rheumatoid Arthritis
A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis
This study will evaluate the safety \& efficacy of Certolizumab Pegol (CZP) as additional medication to Methotrexate (MTX) in Chinese subjects with Rheumatoid Arthritis.
- Trial name
- RAPID-C (NCT02151851)
- Testing
- Certolizumab Pegol, Methotrexate
- Where
- 30 sites in China
- Volunteers
- 430 people
- Sponsor
- UCB Pharma SA, Belgium
GERD, Acid Reflux Disease
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).
- Conditions
- GERD, Acid Reflux Disease, Heartburn, Regurgitation
- Trial name
- C27 (NCT00703534)
- Testing
- AZD3355, Gelusil®
- Where
- 84 sites in United States
- Volunteers
- 478 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
The purpose of the study is to evaluate efficacy and safety of arbaclofen placarbil (XP19986) versus placebo as adjunctive therapy in subjects with troublesome GERD symptoms despite therapy with approved doses of a Proton Pump…
- Trial name
- NCT00978016
- Testing
- arbaclofen placarbil-Cohort 1, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3
- Where
- 64 sites in United States, Canada
- Volunteers
- 460 people
- Sponsor
- XenoPort, Inc.
Rheumatoid Arthritis
Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)
The objective of this trial is to investigate the efficacy (American College of Rheumatology 20% : ACR20) superiority of two dose regiments of CDP870 versus placebo in combination with MTX in active RA patients who have an…
- Trial name
- NCT00791999
- Testing
- CDP870 400mg, CDP870 200mg, CDP870 100mg
- Where
- 8 sites in Japan
- Volunteers
- 316 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis.
- Conditions
- AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG
- Trial name
- NCT07284420
- Testing
- Efgartigimod IV, Empasiprubart IV
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 70 people
- Sponsor
- argenx
Asthma
Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma
This is a dose-response study to determine how various measurements of airway inflammation respond to high and low dose FlutiForm®, and compared to placebo.
- Trial name
- FLT2503 (NCT00995800)
- Testing
- Fluticasone propionate / Formoterol fumarate
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Mundipharma Research Limited
Rheumatoid Arthritis
A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.
- Trial name
- NCT00160602
- Testing
- Certolizumab Pegol
- Where
- 70 sites in United States, Bulgaria and 13 more
- Volunteers
- 590 people
- Sponsor
- UCB Pharma
Anxiety, Anxiety Disorders
Generalized Anxiety Disorder Adjunct Study
This study is being carried out to see if extended release quetiapine fumarate (Seroquel®XL) when added to standard selective serotonin reuptake inhibitor (SSRI) / serotonin-norepinephrine reuptake inhibitor (SNRI) therapy is…
- Conditions
- Anxiety, Anxiety Disorders, Anxiety Neuroses, Anxiety States
- Trial name
- NCT00534599
- Testing
- quetiapine fumarate XR
- Where
- 53 sites in United States
- Volunteers
- 409 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Switch to Infliximab After Incomplete Response to Etanercept
The purpose of this study, in patients with rheumatoid arthritis who have had an incomplete response to etanercept and methotrexate (MTX), are to evaluate: safety and evidence of therapeutic benefit of infliximab and…
- Trial name
- NCT00317538
- Testing
- infliximab, etanercept
- Volunteers
- 28 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.